123I-Meta-iodobenzylguanidine (MIBG) myocardium scintigraphy in patients showing scans without evidence of dopaminergic deficits (SWEDDs)

Dopamine transporter single-photon emission computed tomography (DAT-SPECT) with 123I-labeled 2 β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) is used to evaluate patients who are clinically presumed to have Parkinson’s disease (PD), because it can identify nigrostriatal degeneration with high sensitivity and specificity [1]. It is improbable that DAT-SPECT wo uld show normal findings in early PD, because 50% or more of striatal neurons have been lost by the time clinical symptoms of PD become manifest [2].

Source: Clinical Neurology and Neurosurgery - June 26, 2017 Category: Neurosurgery Authors: Fumihito Yoshii, Yusuke Moriya, Tomohide Ohnuki, Masafuchi Ryo, Wakoh Takahashi, Saori Kohara, Jun Hashimoto Source Type: research